1-11 of 11
Nicholas Keen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors

Michael Rigby, Gavin Bennett, Liuhong Chen, Gemma E. Mudd, Helen Harrison, Paul J. Beswick, Katerine Van Rietschoten, Sophie M. Watcham, Heather S. Scott, Amy N. Brown, Peter U. Park, Carly Campbell, Eric Haines, Johanna Lahdenranta, Michael J. Skynner, Phil Jeffrey, Nicholas Keen, Kevin Lee
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (12): 1747–1756.
https://doi.org/10.1158/1535-7163.MCT-21-0875
Published: 02 December 2022
View article titled, BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors
Open the PDF for BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors in another window
Includes: Supplementary data
Journal Articles

MMAE Delivery Using the Bicycle Toxin Conjugate BT5528

Gavin Bennett, Amy Brown, Gemma Mudd, Philip Huxley, Katerine Van Rietschoten, Silvia Pavan, Liuhong Chen, Sophie Watcham, Johanna Lahdenranta, Nicholas Keen
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2020) 19 (7): 1385–1394.
https://doi.org/10.1158/1535-7163.MCT-19-1092
Published: 02 July 2020
View article titled, MMAE Delivery Using the <em>Bicycle</em> Toxin Conjugate BT5528
Open the PDF for MMAE Delivery Using the <em>Bicycle</em> Toxin Conjugate BT5528 in another window
Includes: Supplementary data
Journal Articles

Abstract C066: BT5528, a Bicycle Toxin Conjugate targeting EphA2: mechanism of action and clinical translation

Gavin Bennett, Amy Brown, Gemma Mudd, Johanna Lahdenranta, Nicholas Keen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): C066.
https://doi.org/10.1158/1535-7163.TARG-19-C066
Published: 01 December 2019
View article titled, Abstract C066: BT5528, a Bicycle Toxin Conjugate targeting EphA2: mechanism of action and clinical translation
Journal Articles

Abstract C061: BT8009, a Bicycle Toxin Conjugate targeting Nectin-4, shows target selectivity, and efficacy in preclinical large and small tumor models

Michael Rigby, Gavin Bennett, Liuhong Chen, Gemma Mudd, Paul Beswick, Helen Harrison, Sophie Watcham, Heather Allen, Amy Brown, Katerine Van Rietschoten, Philip Jeffrey, Peter U Park, Eric Haines, Nicholas Keen, Johanna Lahdenranta
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): C061.
https://doi.org/10.1158/1535-7163.TARG-19-C061
Published: 01 December 2019
View article titled, Abstract C061: BT8009, a Bicycle Toxin Conjugate targeting Nectin-4, shows target selectivity, and efficacy in preclinical large and small tumor models
Journal Articles

Abstract B135: The mechanism of action of BT1718, a novel small-molecule drug conjugate for the treatment of solid tumors expressing MT1-MMP

Gavin Bennett, Mike Rigby, Bob Lutz, Peter Park, Nicholas Keen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): B135.
https://doi.org/10.1158/1535-7163.TARG-17-B135
Published: 01 January 2018
View article titled, Abstract B135: The mechanism of action of BT1718, a novel small-molecule drug conjugate for the treatment of solid tumors expressing MT1-MMP
Journal Articles

Abstract C151: Systematic discovery of cancer dependencies through deep coverage pshRNA screens

Michael Schlabach, Eric Billy, Konstantinos Mavrakis, Greg Hoffman, Tobias Schmelzle, Francesco Hofmann, Nicholas Keen, Frank Stegmeier, William Sellers
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): C151.
https://doi.org/10.1158/1535-7163.TARG-15-C151
Published: 01 December 2015
View article titled, Abstract C151: Systematic discovery of cancer dependencies through deep coverage pshRNA screens
Journal Articles

Abstract C55: Discovery and optimization of inhibitors of the KIFC1 motor protein.

Michelle L. Lamb, Jiaquan Wu, Keith Mikule, Wendy Wang, Nancy Su, Philip Petteruti, Farzin Gharahdaghi, Erin Code, Xiahui Zhu, Kelly Jacques, Zhongwu Lai, Tao Zhang, David Boulay, Gurmit Grewal, Nicholas Keen, Bin Yang, Claudio Chuaqui, Claudio Chuaqui, Huawei Chen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C55.
https://doi.org/10.1158/1535-7163.TARG-13-C55
Published: 01 November 2013
View article titled, Abstract C55: Discovery and optimization of inhibitors of the KIFC1 motor protein.
Journal Articles

Abstract A11: Modeling drug response and resistance using patient-derived xenograft models.

Guizhi Yang, John Green, Colleen Kowal, Shawn Cogan, Roberto Velazquez, John Monahan, Joshua Korn, Nicholas Keen, Juliet Williams, Hui Gao
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A11.
https://doi.org/10.1158/1535-7163.TARG-13-A11
Published: 01 November 2013
View article titled, Abstract A11: Modeling drug response and resistance using patient-derived xenograft models.
Journal Articles

Abstract C149: The PKC inhibitor Sotrastaurin selectively inhibits the growth of GNAQ mutant uveal melanoma.

Rosemary Barrett, Ribo Guo, Jing Yuan, Vesselina Cooke, Anthony Vattay, Joshua Korn, Guiqing Liang, Xin Li, Ramu Thiruvamoor, Andrew Wylie, Anka Bric, Nicholas Keen, William Sellers
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C149.
https://doi.org/10.1158/1535-7163.TARG-13-C149
Published: 01 November 2013
View article titled, Abstract C149: The PKC inhibitor Sotrastaurin selectively inhibits the growth of GNAQ mutant uveal melanoma.
Journal Articles

Abstract PR02: LEE011: An orally bioavailable, selective small molecule inhibitor of CDK4/6– Reactivating Rb in cancer.

Sunkyu Kim, Alice Loo, Rajiv Chopra, Giordano Caponigro, Alan Huang, Sadhna Vora, Sudha Parasuraman, Steve Howard, Nicholas Keen, William Sellers, Christopher Brain
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): PR02.
https://doi.org/10.1158/1535-7163.TARG-13-PR02
Published: 01 November 2013
View article titled, Abstract PR02: LEE011: An orally bioavailable, selective small molecule inhibitor of CDK4/6– Reactivating Rb in cancer.
Journal Articles

Abstract PR06: A functional screen of the epigenome identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers.

Zainab Jagani, Gregory Hoffman, Rami Rahal, Frank Buxton, Gregory McAllister, Kay Xiang, Elizabeth Frias, Janina Huber, Alicia Lindeman, Dongshu Chen, Linda Bagdasarian, Rodrigo Romero, Nadire Ramadan, Tanushree Phadke, Kristy Haas, Mariela Jaskelioff, Boris Wilson, Matthew Meyer, Margaret E. McLaughlin, Charles WM Roberts, Vic Myer, Jeff Porter, Nicholas Keen, Craig Mickanin, Frank Stegmeier
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): PR06.
https://doi.org/10.1158/1535-7163.TARG-13-PR06
Published: 01 November 2013
View article titled, Abstract PR06: A functional screen of the epigenome identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers.